SCHEMBL2643744

SCHEMBL2643744

O=C(O)c1cc(Oc2ccc(C(=O)N3CCC3)cc2)c2c(c1)OC(C(F)F)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MBTD1 Q05BQ5 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
FFAR1 O14842 1/20 0.37
HPGD P15428 4/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
SLC6A4 P31645 4/20 0.36
HRH3 Q9Y5N1 4/20 0.36
HTT P42858 1/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A3 Q01959 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644232 0.87 GCK (0.35) FFAR1LMNA
SCHEMBL644889 0.82 GCK (0.59)
SCHEMBL2669379 0.82 GCK (0.35) SLC6A4HRH3SLC6A2SLC6A3
SCHEMBL2644248 0.81 HPGD (0.40) ALDH1A1MAPTL3MBTL1MBTD1L3MBTL3
SCHEMBL643904 0.75 GCK (0.54) ALDH1A1MAPTL3MBTL1HPGDHSD17B10
SCHEMBL2644253 0.73 GCK (0.49) L3MBTL1MBTD1L3MBTL3FFAR1SLC6A4
SCHEMBL2643898 0.73 GCK (0.52) ALDH1A1MAPTL3MBTL1MBTD1L3MBTL3
SCHEMBL643957 0.72 GCK (0.58)
SCHEMBL2644917 0.72 MEN1 (0.45) HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL2644508 0.71 CPS1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 ALDH1A1 1370/4885MAPT 3264/4885L3MBTL1 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.